Treatment of atopic eyelid disease using topical tacrolimus following corticosteroid discontinuation in a patient with open-angle glaucoma

被引:16
作者
Kymionis, GD [1 ]
Tsilimbaris, MK [1 ]
Iliaki, OE [1 ]
Christodoulakis, E [1 ]
Siganos, CS [1 ]
Pallikaris, JG [1 ]
机构
[1] Univ Crete, Sch Hlth Sci, Div Med, Dept Ophthalmol, Iraklion 71100, Greece
关键词
atopic eyelid disease; corticosteroids; glaucoma; tacrolimus;
D O I
10.1097/01.ico.0000127484.46584.f6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report a case of atopic eyelid disease treatment using topical tacrolimus in a patient with open-angle glaucoma following corticosteroid discontinuation. Design: Interventional case report. Methods: A 59-year-old white man with a history of treated open-angle glaucoma (latanoprost 0.005%) was referred to our department for atopic eyelid disease. The patient had received previous treatment with topical corticosteroid ointments (hydrocortisone acetate 1%/dexamethasone 0.1% ointments) that, even though they were effective in controlling atopic eyelid disease, were complicated by markedly elevated intraocular pressure (IOP) (steroid responder). Topical steroids were discontinued while other treatment modalities (such as eyelid hygiene, artificial tears, topical antihistamine drugs, topical mast cell stabilizers, or topical/oral antibiotics) were proven ineffective. Results: Topical tacrolimus 0.03% ointment (Protopic-, Fujisawa, Dublin, Ireland) was applied to the eyelid skin twice daily. An improvement of eyelid inflammation was observed while eczematous skin lesions and erosions were resolved within 15 days. After 6 months of continued topical tacrolimus treatment, there was no evidence of atopic dermatitis recurrence. During this period IOP remained controlled without any evidence of deregulation. Conclusions: Treatment of atopic eyelid disease with topical tacrolimus, following corticosteroid discontinuation in a steroid responder patient with open-angle glaucoma, seems to be an effective alternative treatment to corticosteroids without the risk of IOP increase.
引用
收藏
页码:828 / 830
页数:3
相关论文
共 8 条
[1]   Treatment of persistent glaucoma secondary to periocular corticosteroids [J].
Akduman, L ;
Kolker, AE ;
Black, DL ;
DelPriore, LV ;
Kaplan, HJ .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 122 (02) :275-277
[2]  
Clark A F, 1995, J Glaucoma, V4, P354
[3]  
HERNANDEZ MR, 1983, INVEST OPHTH VIS SCI, V24, P1612
[4]   FK-506, A NOVEL IMMUNOSUPPRESSANT ISOLATED FROM A STREPTOMYCES .2. IMMUNOSUPPRESSIVE EFFECT OF FK-506 INVITRO [J].
KINO, T ;
HATANAKA, H ;
MIYATA, S ;
INAMURA, N ;
NISHIYAMA, M ;
YAJIMA, T ;
GOTO, T ;
OKUHARA, M ;
KOHSAKA, M ;
AOKI, H ;
OCHIAI, T .
JOURNAL OF ANTIBIOTICS, 1987, 40 (09) :1256-1265
[5]   FK 506 ointment 0.1% -: A new therapeutic option for atopic blepharitis.: Clinical trial with 14 patients [J].
Mayer, K ;
Reinhard, T ;
Reis, A ;
Böhringer, D ;
Sundmacher, R .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2001, 218 (11) :733-736
[6]   Topical tacrolimus treatment of atopic eyelid disease [J].
Rikkers, SM ;
Holland, GN ;
Drayton, GE ;
Michel, FK ;
Torres, MF ;
Takahashi, S .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (03) :297-302
[7]  
TUFT SJ, 1991, OPHTHALMOLOGY, V98, P150
[8]  
VIE R, 1980, ACTA DERM-VENEREOL, V60, P541